https://doi.org/10.1056/NEJMoa2516491
18h ago· 1 min readNews
mRNA-1010 flu vax for adults ≥50 boosts safety and efficacy! Phase 3: 37.5μg (12.5μg/strain); promising vs. current shots. Details in NEJM. PMID:42090792, N Engl J Med 2026, @NEJM https://doi.org/10.1056/NEJMoa2516491 #Medsky #Pharmsky #RNA #ASHG #ESHG 🧪
You might also wanna read
Personalized mRNA Cancer Vaccine Shows 49% Risk Reduction at 5-Year Follow-up
Moderna and Merck report promising 5-year follow-up results for their personalized mRNA cancer vaccine combined with Keytruda immunotherapy.
arstechnica.com·4mo ago
FDA Issues Refusal-to-File Letter to Moderna for mRNA Influenza Vaccine
The article criticizes the FDA's recent actions under the new administration, particularly focusing on a Refusal-to-File (RTF) letter issued
marginalrevolution.com·3mo agoUndisclosed Deaths in the Pfizer mRNA Covid-19 Vaccine Trial [pdf]
jpands.org·6mo ago
US Vaccine Panel Chair Says Polio and Other Shots Should Be Optional
nytimes.com·4mo ago
Study Examines Association Between mRNA COVID-19 Vaccination and 4-Year All-Cause Mortality in French Adults Aged 18-59
This cohort study analyzes data from over 28 million French adults aged 18-59 to examine the association between mRNA COVID-19 vaccination a
jamanetwork.com·6mo agoEfficient mRNA delivery to resting T cells to reverse HIV latency
nature.com·1y ago